CliffBio
biologic

Rybrevant

amivantamab-vmjw

Loss of exclusivityMay 2033projected — 12-year biologic exclusivity estimate
CompanyJanssen Biotech →See this company's full patent-cliff portfolio

Drug detail

Brand nameRybrevant
Active ingredientamivantamab-vmjw
Strength350MG/7ML (50MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalMay 2021
Marketing statusRx

More from Janssen Biotech

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Rybrevant patent cliff — loss of exclusivity May 2033 | CliffBio